Gout Is Prevalent but Under-Registered Among Patients With Cardiovascular Events: A Field Study

Irene Calabuig1, Miguel Gómez-Garberí2, Mariano Andrés1,2

  • 1Sección de Reumatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.

Frontiers in Medicine
|October 29, 2020
PubMed

Insights

Gout is highly prevalent in hospitalized cardiovascular disease patients, affecting 15%. Many cases go undiagnosed and undertreated, highlighting a critical gap in managing this independent cardiovascular risk factor.

Area of Science:

  • Cardiology
  • Rheumatology
  • Epidemiology

Background:

  • Gout is a significant independent risk factor for cardiovascular (CV) disease, contributing to morbidity and mortality.
  • Understanding gout's prevalence and management in hospitalized CV patients is crucial but currently undefined.

Purpose of the Study:

  • To determine the prevalence, characteristics, and management of gout in patients hospitalized for cardiovascular events.
  • To identify predictors of gout in this specific patient population.

Main Methods:

  • An observational, descriptive, cross-sectional study involving 266 patients admitted for CV events.
  • Gout diagnosis confirmed using 2015 ACR/EULAR criteria; data collected via interviews and medical records.
  • Multivariate logistic regression used to identify predictors of gout.

Main Results:

  • Gout prevalence was 15.0% (40/266 patients), with diagnosis absent in 35% of records and under-registration in discharge reports.
  • Independent predictors for gout included prior hyperuricemia (OR 2.9) and chronic kidney disease (OR 3.0).
  • Only 50% of gout patients received urate-lowering therapy upon admission, with suboptimal serum urate control.

Conclusions:

  • Gout is highly prevalent in hospitalized cardiovascular patients, indicating significant under-recognition.
  • Suboptimal management of gout in this population necessitates improved awareness and treatment strategies.
  • Addressing gout in CV patients is essential for mitigating cardiovascular risk.

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
278
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
203
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
633
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
296
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
388
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.0K